INSULIN RESISTANCE AND ATHEROSCLEROSIS STUDY (IRAS)

胰岛素抵抗和动脉粥样硬化研究(IRAS)是一项多中心研究 胰岛素抵抗与心血管疾病关系的研究进展 疾病(CVD)及其危险因素在一个三族(非裔美国人， 西班牙裔和非西班牙裔白人)人口年龄在40岁至69岁之间 基线。研究人群的选择是为了确保足够数量的 性别和糖耐量组的参与者(正常血糖， 耐受性受损和非胰岛素依赖型糖尿病[NIDDM])。 IRAS是第一个包含详细信息的大型流行病学研究 胰岛素敏感性和分泌的测量。在前四年 在多年的资助下，IRAS调查人员成功地设计和 实施了研究的第一阶段--对 1625名参与者。 目前的提案要求再提供五年的资金 对IRAS队列的前瞻性跟踪和复查。所请求的 资助期分为三个阶段。在第一阶段(Y05和 Y06)，调查人员建议进行一项子研究，以解决 NIDDM患者的胰岛素敏感性测定。这 子研究将评估测量胰岛素的几种替代技术 大约115名患有NIDDM的非IRAS志愿者的敏感性。在……里面 此外，将每年联系所有IRAS参与者以了解事件 心血管等重大健康事件。在第二阶段 (Y07和Y08)，将对IRAS队列进行后续检查 其目的是确定胰岛素变化的预测因素 敏感性、心血管危险因素、动脉粥样硬化的测量 发展，以及突发的心血管事件。此外，从头到尾 头四年(Y05-Y08)，将继续进行重大努力 致力于分析和报告来自 第一次IRAS检查。最后阶段(Y09)将包括数据库 关闭和存档，并分析和报告纵向 结果。

The Insulin Resistance and Atherosclerosis Study (IRAS) is a multicenter study of the relationship between insulin resistance and cardiovascular disease (CVD) and its risk factors in a tri-ethnic (African-American, Hispanic, and non-Hispanic white) population aged 40 to 69 years at baseline. The study population was selected to insure adequate numbers of participants within gender and glucose tolerance groups (normoglycemia, impaired tolerance, and non-insulin dependent diabetes mellitus [NIDDM]). IRAS is the first large epidemiologic study to include detailed measurements of insulin sensitivity and secretion. During the first four years of funding, the IRAS Investigators successfully designed and implemented the first phase of the study--a cross-sectional evaluation of 1,625 participants. The current proposal requests an additional five years of funding for the prospective follow-up and reexamination of the IRAS cohort. The requested funding period consists of three phases. During the first phase (Y05 and Y06), the investigators propose to conduct a substudy to address the measurement of insulin sensitivity in individuals with NIDDM. This substudy will evaluate several alternate techniques for measuring insulin sensitivity in approximately 115 non-IRAS volunteers with NIDDM. In addition, all IRAS participants will be contacted annually for incident cardiovascular and other major health events. During the second phase (Y07 and Y08), a follow-up examination of the IRAS cohort will be conducted with the goal of determining predictors of changes in insulin sensitivity, cardiovascular risk factors, measures of atherosclerosis development, and incident cardiovascular events. Additionally, throughout the first four years (Y05-Y08), there will be a continued major effort devoted to the analysis and reporting of the cross-sectional data from the first IRAS examination. The final phase (Y09) will include database closure and archival, and analysis and reporting of the longitudinal results.